Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access

Executive Summary

US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.

You may also be interested in...



Priority Review Voucher Fee Rises 4.6% For Fiscal 2018

As of Oct. 1, the fee for rare pediatric disease and tropical disease priority review vouchers will be $2.83m; the increase follows a slight decline in FY 2017.

Keeping Track: US FDA's Late Summer Approval Extravaganza Stars Three Novel Agents, Features Return Of Mylotarg

Kymriah, Vabomere, and benzidazole approvals joined by new indications for Austedo, Faslodex.

FDA's NDA And BLA Approvals: Kymriah, Vabomere, Cyltezo

Original new drugs and biologics recently approved by US FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel